生产企业：Immunic, Inc.
Vidofludimus (vidofludimus calcium, IMU-838) is an investigational oral therapy developed by Immunic, Inc. for multiple sclerosis, currently being evaluated in Phase 3 clinical trials for relapsing MS. It combines neuroprotective effects as a first-in-class nuclear receptor-related 1 (Nurr1) activator with anti-inflammatory and anti-viral effects by selectively inhibiting dihydroorotate dehydrogenase (DHODH).
Vidofludimus (vidofludimus calcium, IMU-838) is an investigational oral therapy developed by Immunic, Inc. for multiple sclerosis, currently being evaluated in Phase 3 clinical trials for relapsing MS. It combines neuroprotective effects as a first-in-class nuclear receptor-related 1 (Nurr1) activator with anti-inflammatory and anti-viral effects by selectively inhibiting dihydroorotate dehydrogenase (DHODH).
Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH).
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
